NCT07177482Recruiting
ImmunoPET Targeting Trophoblast Cell-surface Antigen 2 (Trop-2) in Craniopharyngioma Patients
Source: ClinicalTrials.gov · Last updated 17 Sept 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
This study aims to investigate 68Ga-MY6349, an immune-PET tracer targeting trophoblast cell surface antigen 2 (Trop2), for the noninvasive diagnosis of craniopharyngioma in vivo.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- First submitted
- 10 Sept 2025
- Start date
- 4 Jul 2025
- Primary completion date
- 31 Dec 2026
- Lead sponsor
- Deling Li
- Diseases
- Childhood cancers
- NCT number
- NCT07177482
What you commit to
- Study type: Interventional
- Planned participants: 20
- From 4 Jul 2025 to the primary completion date, 31 Dec 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- concomitant major central nervous system disorders
Other illness
- history of severe allergy or hypersensitivity to intravenous radiographic contrast agents
Other
- severe hepatic or renal dysfunction
- claustrophobia precluding PET/CT or MRI examinations
- pregnancy or breastfeeding
Who the study is looking for
- must be able to provide a written informed consent
- radiologically presumed and/or histologically confirmed craniopharyngioma scheduled for resection
- adequate clinical condition (Karnofsky performance status ≥70)
Age in the registry: 14 years to 80 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Beijing Tiantan Hospital Coordinator of this site? Confirm its status | Beijing | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.